Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110153 | 0.84 | NPC1 (0.50) | ALDH1A1NPC1RAB9APOLBMEN1 | |
| SCHEMBL5110217 | 0.81 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9APOLBDGAT1 | |
| SCHEMBL14207831 | 0.81 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9APOLBDGAT1 | |
| SCHEMBL14207825 | 0.77 | NPC1 (0.56) | ALDH1A1NPC1RAB9APOLBMEN1 | |
| SCHEMBL21617021 | 0.75 | POLB (0.43) | ALDH1A1NPC1RAB9APOLBMEN1 | |
| SCHEMBL29574285 | 0.73 | RAB9A (0.45) | ALDH1A1NPC1RAB9APOLBDGAT1 | |
| SCHEMBL22717358 | 0.73 | RAB9A (0.45) | ALDH1A1NPC1RAB9APOLBDGAT1 | |
| SCHEMBL2134732 | 0.70 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9APOLBDGAT1 | |
| SCHEMBL1145938 | 0.70 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9APOLBMEN1 | |
| SCHEMBL7045809 | 0.70 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092739-A1 | Heterocyclic compounds | SINON CORPORATION (TW) | 2003-05-15 | — | — | US | claimed |
| US-20030092739-A1 | Heterocyclic compounds | SINON CORPORATION (TW) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092739-A1 | Heterocyclic compounds | NOX1, CBR1, DDT | ALDH1A1 503/4885NPC1 2536/4885RAB9A 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.